Myasthenia Gravis Patient Network
Rare Disease Network for Myasthenia Gravis
['FUNDING_OTHER'] · GEORGE WASHINGTON UNIVERSITY · NIH-11171992
This network connects people with myasthenia gravis to researchers to improve diagnosis, find markers in blood and clinical data, and make it easier for patients to join better clinical trials.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | GEORGE WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (WASHINGTON, UNITED STATES) |
| Trial ID | NIH-11171992 on ClinicalTrials.gov |
What this research studies
If you have myasthenia gravis, MGNet brings together clinics, researchers, and patients to collect medical records, symptom tracking, and biospecimens over time. The project uses an electronic medical record–linked app for ongoing monitoring and gathers blood and other samples to search for diagnostic and treatment-responsive biomarkers across MG subtypes. Researchers will validate markers that might predict who responds to therapies and refine outcome measures used in trials. The network aims to speed up early-phase clinical trials and improve how doctors measure and treat MG while sharing findings with patients and clinicians.
Who could benefit from this research
Good fit: Adults and children with any form of myasthenia gravis (AChR-positive, MuSK-positive, thymoma-associated, or seronegative) who can enroll at a participating center or provide remote data or samples are ideal candidates.
Not a fit: People without myasthenia gravis or those seeking an immediate new therapy may not receive direct personal benefit because the network focuses on research, monitoring, and trial readiness rather than delivering treatments.
Why it matters
Potential benefit: If successful, this work could lead to better tests to diagnose MG, markers that predict which treatments will work, and faster, safer clinical trials for patients.
How similar studies have performed: Other rare-disease networks and registries have helped speed trials and identify candidate biomarkers, but many MG biomarkers remain unproven, so this work builds on prior efforts while addressing ongoing gaps.
Where this research is happening
WASHINGTON, UNITED STATES
- GEORGE WASHINGTON UNIVERSITY — WASHINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KAMINSKI, HENRY J — GEORGE WASHINGTON UNIVERSITY
- Study coordinator: KAMINSKI, HENRY J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases